IP Library › Granted Patent US 12,433,862
Granted Patent B2
US 12,433,862 · App. 17/854,027 · Granted Oct 7, 2025

Pharmaceutical compositions and uses directed to lysosomal storage disorders

Inventor: Michael Strupp (Munich, DE)
Assignee: INTRABIO LIMITED
A61K31/198A61K31/13A61P25/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,862
App. No.
17/854,027
Granted
Oct 7, 2025
Kind
B2
Abstract

The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.

Claims (25)

1. A method of treating a lysosomal storage disorder (LSD) or one or more symptoms associated with the LSD in a subject in need thereof comprising:

administering about 250 mg to about 15 g per day of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months,

wherein the LSD is chosen from Niemann-Pick type C disease, Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII, GM1 gangliosidosis, and aspartylglucosaminuria.

2. A method of delaying progression of a lysosomal storage disorder (LSD) or one or more symptoms associated with the LSD over time as compared to typical disease progression in a subject in need thereof comprising: administering about 250 mg to about 15 g per day of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months, wherein the LSD is chosen from Niemann-Pick type C disease, Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII,GM1 gangliosidosis, and aspartylglucosaminuria.

3. A method of reversing progression of a lysosomal storage disorder (LSD) or one or more symptoms associated with the LSD over time in a subject in need thereof comprising: administering about 250 mg to about 15 g per day of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months wherein the LSD is chosen from Niemann-Pick type C disease, Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII,GM1 gangliosidosis, and aspartylglucosaminuria.

4. A method of improving in a subject in need thereof a biochemical marker of a lysosomal storage disorder (LSD) over time comprising: administering about 250 mg to about 15 g per day of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months, wherein the LSD is chosen from Niemann-Pick type C disease, Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII,GM1 gangliosidosis, and aspartylglucosaminuria.

5. A method of providing neuroprotection in a subject having, suspected of having, or at risk of having a lysosomal storage disorder (LSD) or one or more symptoms associated with the LSD comprising: administering a therapeutically effective amount about 250 mg to about 15 g per day of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months, wherein the LSD is chosen from Niemann-Pick type C disease, Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII,GM1 gangliosidosis, and aspartylglucosaminuria.

6. The method according to claim 4 , wherein the biochemical marker is increased lysosomal volume.

7. The method according to claim 1 , wherein the subject is asymptomatic.

8. The method according to claim 4 , wherein the initial administration occurs after the subject has been found to have a genetic and/or biochemical marker of the LSD.

9. The method according to claim 1 , wherein the acetyl-leucine is acetyl-DL-leucine.

10. The method according to claim 1 , wherein the acetyl-leucine has an enantiomeric excess of the L-enantiomer or the D-enantiomer.

11. The method according to claim 1 , wherein the acetyl-leucine is in a single enantiomeric form of either the L-enantiomer or the D-enantiomer.

12. The method according to claim 11 , wherein the single enantiomeric form is the L-enantiomer.

13. The method according to claim 1 , wherein the method comprises administering the acetyl-leucine to the subject in need thereof at a therapeutically effective amount of from about 500 mg to about 15 g per day.

14. The method according to claim 1 , wherein the LSD is chosen from Niemann-Pick type A disease, Niemann-Pick type B disease, and Niemann-Pick type C disease.

15. A method of treating Tay Sachs disease or one or more symptoms associated with Tay Sachs disease in a subject in need thereof comprising:

administering a therapeutically effective amount of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months.

16. The method of claim 15 , wherein the therapeutically effective amount ranges from about 250 mg to about 15 g per day.

17. A method of treating Sandhoff disease or one or more symptoms associated with Sandhoff disease in a subject in need thereof comprising:

administering a therapeutically effective amount of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months.

18. The method of claim 17 , wherein the therapeutically effective amount ranges from about 250 mg to about 15 g per day.

19. A method of treating Niemann Pick Type C disease or one or more symptoms associated with Niemann Pick Type C disease in a subject in need thereof comprising:

administering a therapeutically effective amount of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a duration of greater than 3 months.

20. The method of claim 17 , wherein the therapeutically effective amount ranges from about 250 mg to about 15 g per day.

Priority Claims (4)
GB 1613828 · Aug 11, 2016 · national
GB 1702552 · Feb 16, 2017 · national
GB 1705762 · Apr 10, 2017 · national
GB 1706854 · Apr 28, 2017 · national
Continuity (2)
Continuation 16324301
Related Publication 20220331278A1 · Oct 20, 2022
References Cited (71)
US 10781285B2 · Kim et al. · 2020 [cited by applicant]
US 11400067B2 · Strupp · 2022 [cited by examiner]
US 20020095135A1 · Meeker et al. · 2002 [cited by applicant]
US 20080108702A1 · Przybylski · 2008 [cited by applicant]
US 20090318555A1 · Fabre et al. · 2009 [cited by applicant]
US 20130142888A1 · Rekik · 2013 [cited by applicant]
US 20130317036A1 · Rekik · 2013 [cited by applicant]
US 20150147309A1 · Parenti et al. · 2015 [cited by applicant]
US 20190201359A1 · Strupp · 2019 [cited by applicant]
US 20230210799A1 · Strupp · 2023 [cited by applicant]
CN 103814046A · 2014 [cited by applicant]
EP 3359146A1 · 2018 [cited by applicant]
FR 2749512A1 · 1997 [cited by examiner]
FR 2905600A1 · 2008 [cited by applicant]
JP 2008533102A · 2008 [cited by applicant]
JP 2010503658A · 2010 [cited by applicant]
JP 2013527222A · 2013 [cited by applicant]
JP 2013544275A · 2013 [cited by applicant]
JP 2015518872A · 2015 [cited by applicant]
JP 2019507819A · 2019 [cited by applicant]
JP 2019524822A · 2019 [cited by applicant]
RU 2012151575A · 2014 [cited by applicant]
WO WO2006097527A1 · 2006 [cited by applicant]
WO WO2009114729A2 · 2009 [cited by examiner]
WO WO2011151685A1 · 2011 [cited by examiner]
WO WO2013182652A1 · 2013 [cited by applicant]
WO WO2018029657A1 · 2018 [cited by applicant]
Bremova (Neurology vol. 85 pp. 1368-1375. Published Oct. 2015) (Year: 2015). [cited by examiner]
Strupp (Neurology Today published online May 21, 2015) (Year: 2015). [cited by examiner]
Heron (Orphanet Journal of Rare Diseases vol. 7 pp. 1-14 published 2012) (Year: 2012). [cited by examiner]
First Office Action issued in related Saudi Arabia Application No. 960002016 / 2019, filed Apr. 28, 2023. [cited by applicant]
Search Report in Saudi Arabia Application No. 96002016 / 2019, dated Apr. 28, 2023. [cited by applicant]
Bremova, T., Malinová, V., Amraoui, Y., Mengel, E., Reinke, J., Kolníková, M., & Strupp, M. (2015). Acetyl-dl-leucine in Niemann-Pick type C: A case series. Neurology, 85(16), 1368-1375. [cited by applicant]
Parkinson-Lawrence, E. J., Shandala, T., Prodoehl, M., Plew, R., Borlace, G. N., & Brooks, D. A. (2010). Lysosomal storage disease: revealing lysosomal function and physiology. Physiology, 25(2), 102-115. [cited by applicant]
Japanese Notification of Reasons for Rejections, Patent Application No. 2022-001694, Mailing Date: May 7, 2021, Mailing No. 187449. [cited by applicant]
Israeli Notification Prior to Refusal of a Patent Application, Patent Application No. 264610, Mailing Date: Feb. 15, 2023. [cited by applicant]
Schniepp et al., “Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia—a case series,” Cerebellum & Ataxias (2016) (4 pages). [cited by applicant]
Search Report in Chinese Application No. 201780062740X, dated Aug. 14, 2021 (2 pages). [cited by applicant]
Search Report in Russian Application No. 2019106493, dated Oct. 26, 2020. [cited by applicant]
Reagan-Shaw et al (FASEBJ vol. 22 pp. 659-661 published 2007) (Year: 2007). [cited by applicant]
Niemann-Pick Type C: Effects of a therapy with acetyl-DL-leucine and vestibular function: Disseration for Graduate School Systemic Neurosciences der Ludwig-Maximilians-Universitat Munchen. Presented Orally to the public… [cited by applicant]
International Search Report dated Nov. 6, 2017, PCT/IB2017/054928. [cited by applicant]
Lukas et al., “Enzyme Enhancers for the Treatment of Fabry and Pompe Disease,” Molecular Therapy, vol. 23, No. 3, pp. 456-464, Mar. 1, 2015. [cited by applicant]
Porto, C., Ferrara, M. C., Meli, M., Acampora, E., Avolio, V., Rosa, M., . . . & Parenti, G. (2012). Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine. Molecular Therapy, 20(12), … [cited by applicant]
Notification of Reasons for Rejection issued in related Japanese Application No. 2022-001694, mailed Feb. 9, 2023. [cited by applicant]
Second Examination Report issued in related Saudi Arabian Application No. 519401064, filed Sep. 20, 2022. [cited by applicant]
Mario CORTINA-BORJA et al.; “Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials”; Orphanet Journal of Rare Diseases (2018) 13:143. [cited by applicant]
Search Report issued in related Japanese Application No. 2019-507811, mailed Apr. 2, 2021. [cited by applicant]
Baudry M et al., Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia, [cited by applicant]
Becker-Bense S et al., P.37 Effects of acetyl-dl-leucine on the cerebral activation pattern in cerebellar ataxia (FDG-PET study), [cited by applicant]
Cologna SM et al., Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight, [cited by applicant]
Cologna SM et al., Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1, [cited by applicant]
Ferber-Viart C et al., Effects of acetyl-DL-leucine in vestibular patients: a clinical study following neurotomy and labyrinthectomy, [cited by applicant]
Gunther L et al., N-acetyl-l-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus, [cited by applicant]
Jeyakumar M, et al., Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin, [cited by applicant]
Loftus SK et al., Murine model of Niemann-Pick disease: mutation in a cholesterol homeostasis gene, [cited by applicant]
News from the AAN Annual Meeting: Modified Amino Acid Improves Cerebellar Ataxia in Niemann-Pick Type C, a Case Series Shows, [cited by applicant]
Patterson MC et al., Miglustat for treatment of Niemann-Pick C disease: a randomized controlled study, [cited by applicant]
Pelz JO et al., Failure to confirm benefit of acetyl-DL-leucine in degenerative cerebellar ataxia: a case series, [cited by applicant]
Smith D et al., Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1, [cited by applicant]
Strupp M et al., Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series, [cited by applicant]
Strupp M and Bremova T, Acetyl-DL-leucine for treatment Niemann-Pick type C: a case series (S9.004), [cited by applicant]
Vibert N and Vidal PP, In vitro effects of acetyl-dl-leucine (tanganil®) on central vestibular neurons and vestibulo-ocular networks of the guinea pig, [cited by applicant]
Yanjanin NM et al., Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C, [cited by applicant]
Zwergal A et al., Sequential [(18)F]FDG μPET whole-brain imaging of central vestibular compensation: a model of deafferentation-induced brain plasticity, [cited by applicant]
Declaration of Michael Strupp under 37 C.F.R. § 1.132 submitted Mar. 13, 2025 in U.S. Appl. No. 96/050,055 (11 pages). [cited by applicant]
Final Office Action dated Jan. 30, 2025, in U.S. Appl. No. 96/050,055. [cited by applicant]
Heron B et al., Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C, Orphanet J Rare Dis., 2012, 7:361, pp. 1-14. [cited by applicant]
Non-Final Office Action dated Nov. 21, 2024, in U.S. Appl. No. 96/050,055. [cited by applicant]
Notice of Intent to Issue Ex Parte Reexamination Certificate dated Mar. 31, 2025, in U.S. Appl. No. 96/050,055. [cited by applicant]
Response to Final Office Action in U.S. Appl. No. 96/050,055 submitted Mar. 13, 2025 (12 pages). [cited by applicant]